OTCM
ECIA
Market cap202kUSD
Oct 05, Last price
0.01USD
1D
0.00%
Jan 2017
-96.71%
Name
Encision Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Encision Inc. (ECIA), established in 1991 and headquartered in Boulder, Colorado, operates as a medical device firm specializing in the development, manufacturing, and commercialization of proprietary surgical instruments for the U.S. market. The company's core offering revolves around its patented Active Electrode Monitoring (AEM) technology, featured in both surgical instruments and dedicated monitors. This innovative system significantly enhances patient safety and optimizes outcomes during laparoscopic surgical procedures. Encision's AEM instrument portfolio encompasses a diverse array of endo-mechanical tools, such as scissors, graspers, and dissectors, alongside specialized fixed-tip and suction-irrigation electrodes. Beyond these, the company supplies specialized handles designed for complex laparoscopic operations, characterized by their robust shafts and ergonomic designs. They also provide the AEM EndoShield 2 burn protection systems. Complementing these instruments, Encision markets its AEM monitor product line, essential for use in conjunction with its AEM instruments. Distribution of Encision's products occurs through a hybrid sales model, leveraging both direct company representatives and an established network of independent sales agents.
Key people
Robert Fries
Interim President, Interim Chief Executive Officer · since 2025
Brian Jackman
Vice President - Marketing · since 2019
Jason Johnson
Vice President - Sales · since 2022
Brandon Shepard
Vice President, Controller, Treasurer, Corporate Secretary · since 2025
Independent Director · since 1998
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||